Figure 2. Estimated Number of Ischemic Events Prevented and Bleeding Events Caused per 1000 Patients When Treated With Rivaroxaban and Aspirin in Combination, Compared With Aspirin Alone Over 30 Months.

HRCM indicates high-risk comorbidity; HRLP, high-risk limb presentation; MACE, major adverse cardiovascular event; MALE, major adverse limb event.